Cargando…

Light Chain Amyloidosis

Light chain (AL) amyloidosis is caused by a usually small plasma-cell clone that is able to produce the amyloidogenic light chains. They are able to misfold and aggregate, deposit in tissues in the form of amyloid fibrils and lead to irreversible organ dysfunction and eventually death if treatment i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milani, Paolo, Merlini, Giampaolo, Palladini, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5841939/ https://www.ncbi.nlm.nih.gov/pubmed/29531659 http://dx.doi.org/10.4084/MJHID.2018.022

Ejemplares similares

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

The lung in amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient
por: Swuec, Paolo, et al.
Publicado: (2019)

Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis
por: Lavatelli, Francesca, et al.
Publicado: (2021)

Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells
por: Imperlini, Esther, et al.
Publicado: (2017)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study
por: Ami, Diletta, et al.
Publicado: (2016)

Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy
por: Milani, Paolo, et al.
Publicado: (2020)

A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2020)

The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018
por: Palladini, Giovanni, et al.
Publicado: (2023)

Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics
por: Rognoni, Paola, et al.
Publicado: (2021)

A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E. coli
por: Rognoni, Paola, et al.
Publicado: (2013)

Protease‐sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation
por: Mazzini, Giulia, et al.
Publicado: (2021)

S198: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, Efstathios, et al.
Publicado: (2023)

P1714: HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS IN EUROPE
por: Jaccard, A., et al.
Publicado: (2022)

Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity
por: Oberti, Luca, et al.
Publicado: (2017)

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
por: Gertz, Morie A., et al.
Publicado: (2023)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group
por: Maurer, Mathew S., et al.
Publicado: (2022)

Bone Marrow Microenvironment in Light-Chain Amyloidosis: In Vitro Expansion and Characterization of Mesenchymal Stromal Cells
por: Valsecchi, Chiara, et al.
Publicado: (2021)

Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis
por: Nuvolone, Mario, et al.
Publicado: (2022)

Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication
por: Baker, Kelty R.
Publicado: (2022)

Cryo-EM structure of ex vivo fibrils associated with extreme AA amyloidosis prevalence in a cat shelter
por: Schulte, Tim, et al.
Publicado: (2022)

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, E., et al.
Publicado: (2022)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis
por: Stelmach-Gołdyś, Agnieszka, et al.
Publicado: (2022)

Multidisciplinary supportive care in systemic light chain amyloidosis
por: Maroun, Bou Zerdan, et al.
Publicado: (2022)

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK
por: Kastritis, E., et al.
Publicado: (2022)

Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p
por: Wong, Sandy W., et al.
Publicado: (2018)

AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
por: Palladini, Giovanni, et al.
Publicado: (2022)

Recent advances in understanding and treating immunoglobulin light chain amyloidosis
por: Badar, Talha, et al.
Publicado: (2018)

Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach
por: Hwa, Yi L., et al.
Publicado: (2019)

COVID-19 and Light Chain Amyloidosis, Adding Insult to Injury
por: Crees, Zachary D., et al.
Publicado: (2022)

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
por: Zhang, Kathleen W., et al.
Publicado: (2019)

Systemic amyloidoses and proteomics: The state of the art
por: Lavatelli, Francesca, et al.
Publicado: (2016)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
por: Hasib Sidiqi, M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d8kqmfa811ut06r61gd8nvmcue